Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are
revolutionizing cancer treatment. To unravel the genomic determinants of response to this therapy, …

Despite signs of infection—including taste loss, dry mouth and mucosal lesions such as
ulcerations, enanthema and macules—the involvement of the oral cavity in coronavirus disease …

Background There is increasing recognition of a prothrombotic state in COVID-19. Post-mortem
examination can provide important mechanistic insights. Methods We present a COVID-…

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By mapping 55 neoantigen-…

Indoleamine 2,3-dioxygenase (IDO) has been described as a major mechanism of
immunosuppression in tumors, though the mechanisms of this are poorly understood. Here, we find …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors
evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of …

Group 2 innate lymphoid cells (ILC2s) regulate inflammation and immunity in mammalian
tissues 1 , 2 . Although ILC2s are found in cancers of these tissues 3 , their roles in cancer …

Adoptive cellular therapy (ACT) targeting neoantigens can achieve durable clinical responses
in patients with cancer. Most neoantigens arise from patient-specific mutations, requiring …

PURPOSE Metastatic breast cancer (mBrCa) is most often an incurable disease with only
modest responses to available immunotherapies. This study investigates the immunogenicity …

A significant proportion of cancer patients do not respond to immune checkpoint blockade.
To better understand the molecular mechanisms underlying these treatments, we explored …